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2.	 Interleukin-10	 delivered	 to	 HSC	 significantly	 affects	 macrophage	 profiles	
within	the	liver.	(This	thesis)
3.	 The	 mild	 and	 mixed	 responses	 seen	 after	 administration	 of	 native	 Inter-
leukin-10	is	most	likely	induced	by	a	combination	of	local	effects	(leading	to	
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General introduction,  
scope and outline of the thesis
“Now, why is the stomach surrounded by the liver?  
Is it in order that the liver may warm it and it may in turn warm the food?  
This is indeed the very reason why it is closely clasped by the lobes of the liver, 
as if by fingers.” -- Galen, ca. 200 A.D
Chapter 1
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and Physiology of the Liver (4to,	4	plates,	London,	1833)	and	his	work	is	regarded	as	the	
first	attempt	of	modern	microscopy	used	in	natural	sciences	[3][4].	




































































prevalence	of	 the	disease	 in	 the	next	 two	decades	 largely	due	 to	 the	emergence	of	
hepatitis	C	virus	(HCV),	the	continued	problem	of	hepatitis	B	virus	(HBV)	infection	
control,	and	the	liver	pathologies	associated	with	obesity	and	chronic	alcohol	abuse.	
Because	of	 the	 reasons	 listed	above,	 the	need	 for	an	effective	 therapy	against	 liver	
fibrosis	is	urgent	[27,40].	




space	of	Disse	which	 leads	to	structural	changes	 in	the	sinusoidal	wall,	 loss	of	 the	
EC	fenestrations	and	the	development	of	a	fibrotic	ECM.	At	the	end	of	this	process,	
















Fig. 1. Matrix and cellular alterations in hepatic fibrosis. (A) Normal liver parenchyma. Sinusoids 
are separated from hepatocytes by a low-density basement membrane-like matrix, which ensures 
metabolic exchange. (B) Deposition of ECM in the space of Disse leads to loss of both endothelial 
fenestrations and hepatocyte microvilli, which results in impairment of normal metabolic exchange. 
Permission obtained from Elsevier Ltd © Hernandez-Gea V., Friedman S.L. Annu. Rev. Pathol. 











Hepatic	 fibrosis	 and	 even	 cirrhosis	 are	 known	 to	 be	 reversible	 if	 the	underly-
ing	cause	is	successfully	removed	[54][55][56][57]	[58][59][60].	Animal	studies	have	

































like	 phenotype	 develops.	The	perpetuation phase	 refers	 to	 the	 ability	 of	 activated	
HSCs	to	maintain	their	activated	status,	via	auto	and	paracrine	stimulation,	and	to	
secrete	excess	of	ECM	components;	especially	collagens	type	1	and	III	[20][70].	The 
resolution	 of	hepatic	fibrosis	 is	 supported	by	 strong	evidences,	 although	 there	 are	
still	doubts	about	its	complete	reversibility.	A	critical	mechanism	that	underlines	the	
reversion	of	liver	fibrosis	is	HSC	apoptosis,	senescence	or	quiescence	[71-73].
Fig. 2. HSC activation. Initiation is stimulated by soluble stimuli such as oxidant stress signals 
(reactive oxygen intermediates), apoptotic bodies, LPS and paracrine stimuli from neighboring 
cell types including Kupffer cells, sinusoudal endothelium and hepatocytes. Initiation is followed 
by perpetuation. Proliferation, contractility, fibrogenesis, altered matrix degradation, chemo-
taxis and inflammatory signaling are specific phenotypic changes characteristics of perpetuation. 
Resolution of hepatic fibrosis, which occurs following clearance of the primary liver disease, leads 
to loss of activated HSCs, either through apoptosis, senescence or reversion of activated cells to a 
more quiescent phenotype. 















Fig. 3. Origin of hepatic myofibroblast-like cells.
Permission obtained from Elsevier Ltd © Forbes S.J, Parola M. Best practice & clinical gastroen-
terology 25 (2011) 207-217.





































Macrophage	 activation	 and	differentiation	 into	 subtypes	 is	 a	 complex	 and	dy-
namic	process	 in	which	 the	 same	macrophage	can	 transdifferentiate	 several	 times	
and	play	different	roles	in	the	process	of	inflammation,	and	fibrosis	progression	and	






es:	 host-defense	 macrophages,	 wound-healing	 (or	 scar-associated)	 macrophages,	





















respectively,	 is	on	chromosome	1.	 It	 encodes	5	exons	which	are	 separated	by	 four	









posed	of	2	different	 chains,	 IL-10R1	and	 IL-10R2	 [114,115].	 Interleukin-10	dimer	








IL-10 in liver fibrosis















and	 antifibrotic	 properties	 in	 the	 liver	 [128-131].	 IL-10	 can	 downregulate	 several	






















In	 the	 other	hand,	 several	 in vivo	 studies	 have	 shown	 that	 IL-10	possess	 pro-
fibrotic	 effects	 rather	 than	antifibrotic.	Mice	genetically	deficient	 in	 IL-10	develop	
reduced	lung	fibrosis	in	response	to	silica	particles	[147][148].	As	IL-10(-/-)	mice	dis-
played	a	downregulation	of	TGF-β	by	alveolar	macrophages	(AM)	and	an	upregula-
tion	of	 prostaglandin	E2	 (PGE2),	 it	was	 hypothesized	 that	 the	 profibrotic	 activity	
of	IL-10	in	lungs	could	be	mediated	by	the	induction	of	TGF-β	expression	in	lung	
macrophages	and	the	inhibition	of	PGE2	secretion	by	fibroblasts,	both	induced	by	
IL-10	[149].	Other	studies,	using	a	 transgenic	mice	model	 that	 is	characterized	by	
lung-	specific	human	IL-10-overexpression,	 showed	 increased	 tissue	 inflammation	







was	 noticeable	 in	 some	 studies	 [149,154-157].	 So,	 IL-10	 has	 important	 inhibitory	
functions	in	inflammation	but	while	many	reports	describe	anti	fibrotic	effects	of	IL-
10,	just	as	many	describe	pro-fibrotic	effects	of	this	cytokine.











General introduction, scope and outline of the thesis
21
1Fig. 4 
Fig. 4. IL-10-IL-10R interaction. The cellular IL-10R is a complex composed of the CRF2 mem-
bers IL-10R1 and IL-10R2. IL-10 first binds IL-10R1. This interaction apparently leads to a 
comformation change of the cytokine creating a binding site for IL-10R2.








IL-10	does	not	 significantly	 induce	 STAT3	 activation	 in	hepatocytes,	 but	 suggests	
it	 may	 activate	 this	 pathway	 in	 non-parenchymal	 cells	 and	 the	 hepatoprotective	







































































ment	of	liver	fibrosis	as	wells	as	for	unraveling	IL-10-specific	effects	on	HSC	in vivo during 
fibrogenesis.	This	will	be	described	in	more	detail,	in	the	scope	and	aim	of	this	thesis.






















mannose-6-phosphate	 (M6P-HSA)	 or	 with	 PDGF-receptor	 recognizing	 peptides	
(PPB-HSA).	M6P-HSA	 binds	 to	 the	M6P/Insulin-like	 Growth	 Factor	 II	 receptor,	
whereas	PPB-HSA	binds	to	the	Platelet	Derived	Growth	factor	Receptor	(PDGF-R).	
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the	 selective	 targeting	 of	 the	 apoptosis-inducing	 drug	 15-deoxy-D12,	 14-prostaglandin	 J2	
(15dPGJ2)	with	two	different	HSC	carriers:	human	serum	albumin	modified	with	the	sugar	
mannose-6-phosphate	 (M6PHSA)	 or	 albumin	modified	 with	 PDGF-receptor	 recognizing	
peptides	(pPBHSA).	
Methods and Results.	After	chemical	conjugation	of	15dPGJ2	to	the	carriers,	the	constructs	
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HSA	 was	 purchased	 from	 the	 Central	 Laboratory	 of	 Blood	 Transfusion	 Services	
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to	20 mg	 (0.25 μmol)	M6PHSA	or	pPBHSA	(dissolved	 in	PBS,	4 mg/ml)	 in	 ratio	







Rat Hepatic Stellate Cell Isolation

































The	Alamar	blue	 conversion	was	measured	with	 a	fluorimeter	 [27].	These	 experi-
ments	were	performed	with	cells	of	three	separate	HSC	isolations.
Animal Model of Liver Fibrosis
To	induce	liver	fibrosis,	rats	(220–240 g)	were	subjected	to	bile	duct	ligation	(BDL)	
under	 isoflurane/O2/N2O	 anesthesia.	The	 rats	 were	 used	 for	 further	 experiments	
















livers	was	used	to	 localize	 the	carrier.	Therefore,	 livers	were	double-stained	with	a	
polyclonal	antibody	against	HSA	(MP	Biomedicals,	Zoetermeer,	The	Netherlands)	
43


















The	 scientific	 use	 of	 human	 liver	 tissue	was	 approved	 by	 the	Medical	 Ethical	
Committee	of	the	University	Medical	Center	Groningen	(The	Netherlands).
Statistics




















approximately	 33	M6P	 groups	 to	 albumin	 significantly	 increases	 the	 net	 negative	
charge	of	the	protein,	which	implicates	that	the	scavenger	receptor	might	be	involved	
in	the	uptake	of	M6PHSA	by	HSC.	
Fig.  1. Binding of the conjugates 125I–15dPGJ2-M6PHSA (black bars) and 125I–15dPGJ2-
pPBHSA (white bars) to cultures of activated rat HSC. Incubation of 125I-labelled conjugate and 
excess amounts of unlabeled M6PHSA, pPBHSA, the scavenger receptor antagonist polyinosinic 
acid (PIA), and HSA was performed to assess receptor-specific uptake of the conjugates by the 
HSC. The results of separate experiments with three different HSC isolations are expressed as the 


































both	 conjugates	were	 still	 able	 to	 reduce	 the	HSC	viability,	 although	 the	dose–re-
sponse	curve	was	somewhat	shifted	to	the	right	(Fig. 2b,	69%	reduction	at	250 μg/ml	







Fig. 2. Effect of different 15dPGJ2 forms on the viability of isolated activated HSC. (a) 15dPGJ2, 
(b) 15dPGJ2-M6PHSA and the carrier M6PHSA control, (c) 15dPGJ2-pPBHSA and the carrier 
pPBHSA control. The experiments were performed under serum starvation (black bars) or in the 
presence of 10% FCS (white bars). Of both conjugates, the estimated concentration of 15dPGJ2 
present in 15dPGJ2-M6PHSA (6 molecules drug/protein) or 15dPGJ2-pPBHSA (8 molecules 
drug/protein) is depicted as well as their protein concentrations. The control cells (incubated 
with vehicle) are set at 100% viability and control wells without cells are set as 0% viability. The 
results are expressed as the mean ± SEM (n = 3, * = P < 0.05). 
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Fig. 3. In vivo organ distribution of 125I-labeled 15dPGJ2-M6PHSA (black bars), 15dPGJ2-pP-
BHSA (striped bars), and HSA (white bars) at 15 min after intravenous injection of the com-
pounds in rats with BDL-induced liver fibrosis. 
To	 determine	 the	 cellular	 specificity	 of	 15dPGJ2-M6PHSA	 and	 15dPGJ2-pPBHSA	
within	the	diseased	livers,	we	examined	the	intrahepatic	distribution	of	the	conjugates	in	











Fig. 4. Immunohistochemical localization of 15dPGJ2-M6PHSA (a) and 15dPGJ2-pPBHSA (b) 
in liver of BDL-10d rats, 15 min after intravenous injection of the constructs. Cell-specific locali-
zation was determined by double staining of the livers with an antibody directed against HSA 
(red staining) together with cellular markers to detect HSC (desmin and GFAP; blue staining). 
Magnification 200×. The inserts shows co-localization of the modified HSA together with HSC 
(arrow; magnification 400×). P = portal area. 
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Table I Estimation of the Intrahepatic Distribution of 15dPGJ2-M6PHSA and 15dPGJ2-pPBH-










M6P/IGFII and PDGF-β Receptor Staining in Normal and Cirrhotic Human Livers
Finally,	we	examined	the	expression	of	the	target	receptors	for	our	HSC-specific	carri-
ers	in	histologically	normal	and	cirrhotic	human	livers	(Fig. 5).	Normal	liver	sections	















Fig. 5. Immunohistochemical detection of M6P/IGFII-receptor (a, b and c) and PDGF-β recep-
tor (d, e and f) in healthy human livers (a, d; magnification 20 × 10) and cirrhotic human livers 
(b, magnification 10 × 10, C magnification 4 × 10). A high magnification (c, f; magnification 
400×) shows that cells in the fibrous bands are positive for both receptors. An asterix indicates 
the localization of periseptal hepatocytes, the arrow head shows ductular cholangiocytes, and the 
arrow points to (myo) fibroblasts. PV = portal vein, N = cirrhotic nodule. 
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Discussion





























contrast	 to	 the	cyclopentenone	ring	of	prostaglandins,	 the	carboxylic	acid	group	 is	
not	essential	for	the	biological	activity	[32,33].	In	our	studies,	we	showed	that	both	
conjugates	were	able	to	effectively	reduce	the	viability	of	HSC	in	vitro.	This	implicates	


















rameters	of	15dPGJ2	after	 i.v.	 injection	have	not	been	 reported,	probably	because	






























































































macromolecule	 to	 fibroblast-like	 cells	 in	 fi-
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PEGylation of Interleukin-10  
improves the pharmacokinetic profile  
and enhances the antifibrotic effectivity  
in CCl4-induced fibrogenesis in mice
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cause	 of	 death	worldwide.	 To	 date,	 no	 drug	 is	 available	 for	 this	 condition.	 Interleukin-10	
(IL-10)	 has	 potent	 anti-inflammatory	 and	 antifibrotic	 properties	 but	 its	 short	 half-life	 in	
the	circulation	hampers	 its	clinical	use.	Our	aim	was	therefore	to	modify	IL-10	with	poly-








both	PEGylated	 forms,	whereas	 IL-1β	 levels	were	only	down-regulated	by	5PEGIL-10	and	
20PEGIL-10.	We	conclude	that	PEGylation	of	IL-10	is	a	good	strategy	to	attenuate	liver	fibro-
sis	and	that	5PEGIL-10	is	the	most	effective	conjugate.
Keywords: Interleukin-10; PEGylation; Pharmacokinetic profile; Liver fibrosis; Macrophage
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cytokine	 that	 downregulates	 several	 proinflammatory	 cytokines	 in	 macrophages,	
including	IL-1β	and	IL-6,	and	decreases	the	expression	of	MHC	class	II	molecules	
[8,9].	In vitro,	it downregulates	collagen	1	and	increases	expression	of	matrix	metal-
loproteases	 in	HSC	and	 thus	promotes	degradation	of	 collagens	 I	 and	 III	 [10,11].	





















(5kDa,	20kDa)	and	examined	 the	circulation	 times	and	biological	 effects	 in	a	CCl4-	











ing	 6.4  μL	of	 12.5 mg/mL	5	 kDa	mPEG-NHS	or	 50	mg/mL	20	 kDa	mPEG-NHS	
(NANOCS,	USA;	ratio	1:50),	as	described	before	[21].	The	reaction	was	followed	by	
24	h	dialysis	against	1×	PBS,	using	suitable	dialysis	membranes	(Harvard	Apparatus,	
Holliston,	MA)	 to	 remove	 any	 unreacted	 PEG.	 Presence	 of	 unreacted	 IL-10	 was	











Cells and cell line
RAW 264.7 – Mouse embryonic cell line.	RAW	264.7	cells	(ATCC,	TIB-71)	were	cul-
tured	at	37ºC	and	5%	CO2	in	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM,	Biowhittaker,	
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Assessment of bioactivity in vitro




ing	0.5%	normal	mouse	 serum.	At	 t	=	0,	 25 ng/mL	of	LPS	 (E.coli,	List	Biological	
Laboratories,	INC.,	USA)	was	added	to	the	wells.	Control	cells	were	not	incubated	
with	LPS.	At	 t	=	6 h,	TNF-α	 levels	 in	 the	culture	media	were	determined	using	a	
sandwich	TNF-α	ELISA	kit	 (BD	PharMingen,	USA).	Assays	were	performed	with	
two	different	batches	of	5	and	20PEG-IL-10	and	in	triplicate	for	each	batch.
Animals and experimental model of liver fibrosis
Pathogen-free	 male	 C57BL/6	 mice	 weighing	 20	 to	 22	 g,	 purchased	 from	 Harlan	
(Zeist,	The	Netherlands)	were	used	in	this	study.	Animals	were	housed	under	labora-
tory	conditions	and	received	ad libitum	normal	diet.	The	experimental	protocols	for	
























Immunohistochemistry.	To	access	 the	amount	of	 activated	HSCs,	 livers	were	fix-
ated	in	4%	formalin	and	embedded	in	paraffin.	After	deparaffinization,	4 μm	sections	
were	stained	for	α-SMA	according	to	standard	methods	using	a	monoclonal	antibody	
(Sigma-Aldrich),	 and	 a	 biotinylated	 secondary	 anti-mouse	 IgG	 antibody.	 Staining	
was	visualized	using	the	Vectastain	Elite	ABC	Mouse	IgG	kit	(Vector	Laboratories,	
Burlingame,	 CA).	 Expression	 of	 type	 III	 collagen,	macrophages	 and	 antigen-pre-
senting	cells	was	examined	 in	aceton	fixated	cryostat	 sections	 (4μm)	according	 to	
standard	 indirect	 immunoperoxidase	 methods	 [25]	 with	 goat	 anti-collagen	 III	
(SouternBiotech,	USA),	rat	anti-F4/80	(Serotec)	or	rat	anti-MHC	class	II	(Santa	Cruz	
Biotechnology,	USA)	IgGs,	respectively.	Staining	was	quantified	by	image	analyzing	
techniques,	 using	Multiple	Alignment	Analysis	 (MIAs).	The	 results	were	 given	 as	
percentages	of	positive-stained	areas	divided	by	the	total	area	of	the	section.	
Real-Time PCR.	Isolation	of	total	RNA	from	mice	livers	was	performed	using	the	
RNeasy	kit	 (QIAGEN,	Hilden,	Germany),	 and	 the	amount	of	RNA	was	measured	
with	 the	 NanoDrop	 ND1000	 (Nanodrop	 Technologies,	 NC).	 The	 reverse	 tran-
scriptase	 reaction	 was	 done	 using	 random	 primers	 (Promega).	The	 transcription	
levels	 of	 mice	 IL-1β	 (forward	 5’GCCAAGACAGGTCGCTCAGGG3’	 and	 reverse	
5’CCCCCACACGTTGACAGCTAGG3’)	and	IL-6	 (forward	5’TGATGCTGGTGA-

























Modification and characterization of PEGylated forms of hIL-10
Two	forms	of	PEG	(5	kDa	and	20	kDa)	were	covalently	 linked	to	 lysine	groups	of	
IL-10	as	illustrated	in	Figure	1A.	SDS-PAGE	was	performed	to	analyze	the	molecular	















TNF-α release by macrophage. To	test	whether	the	biological	activity	of	IL-10	was	
affected	by	the	chemical	modification,	in vitro	anti-inflammatory	effects	of	IL-10	
and	its	PEGylated	forms	were	assessed	in	LPS-stimulated	RAW	264.7	cells.	RAW	
cells	 showed	a	 significant	TNF-α	 release	 in	 response	 to	LPS	 as	 compared	 to	 the	
control,	 as	 shown	 in	fig.	 2.	This	 response	 could	 be	 inhibited	 by	 29±6.5%	by	 IL-






Fig. 1. Schematic diagram of the synthesis of PEGylated IL-10. (B) Silver staining of SDS-PAGE 
of IL-10 and its PEGylated forms. Dimeric IL-10 (37KDa; lane I) was modified with 5 KDa 
PEG (lane II) and the new compound had an increased molecular weight (75-80KDa). The 
modification with 20 KDaPEG (lane III) was not detectable after silver staining, but the blot 
shows the complete absence of unmodified IL-10. (C) PEG-staining of SDS-PAGE of IL-10 and 
its PEGylated forms. PEG-positive bands were found at 75–80 kDa for 5PEGIL-10 and at 100–
120 kDa for 20PEGIL-10.
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Fig. 2. Effect of IL-10, 5PEGIL-10 and 20PEGIL-10 on TNFa release by RAW 264.7 cells in vitro. Cells 
were incubated with 50 ng of IL-10, 5PEGIL-10 and 20PEGIL-10, 30 min before a challenge with LPS 
(25 ng/mL). It can be seen that TNF-α production was significantly inhibited by all IL-10 compounds 
(*p< 0.001 compared to LPS-stimulated cells). Results are expressed as mean±SD (n = 3).





































































Fig. 3. Biodistribution of [125 I]IL-10, [125 I]5PEG-IL-10 and [125 I]20PEG-IL-10, at various 
time-points after intravenous injection of tracer amounts in mice with CCL4-induced liver dis-
ease. (A) Results show an increased circulation time of [125 I]5PEG-IL-10 and [125 I]20PEG-
IL-10 in the blood (**p<0.001); (B) Liver accumulation of all three compounds was similar at 
t = 15 min, but uptake at 3 h and 24 h of [125 I]5PEG-IL-10 and [125 I]20PEG-IL-10 was 
increased in the liver (*p<0.01).Results are expressed as mean±SD with n = 3/group/timepoint.
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Effects of PEGylated IL-10 in CCl4 treated mice. 
Since	 the	biological	 activities	of	 IL-10	were	not	altered	 in vitro	 after	PEGylation	
and	 the	 in vivo	 distribution	of	 IL-10	 to	 the	 liver	was	 improved	after	 attachment	
of	PEG,	we	proceeded	to	study	the	 in vivo	effects	of	the	two	PEGylated	forms	of	
IL-10	relative	to	unmodified	IL-10.	For	this	purpose,	we	used	an	acute	CCl4	mice	
model,	 characterized	by	 activation	of	HSC	 (assessed	by	α-SMA	expression)	 and	
deposition	of	fibrilar	collagen	(assessed	by	collagen	type	III	expression)	in	areas	of	
CCL4	induced	cell	damage,	as	depicted	in	figure	4A	and	B.	We	analyzed	the	effects	













a	64%	decline	 in	MHC	class	 II	expression	was	 found	 in	 the	5PEGIL-10	 treatment	
group	 (p<0.01)	compared	 to	 the	control	group	 (fig	5A	and	5C),	whereas	 IL-10	or	
20PEGIL-10	did	not	induce	a	significant	effect.	Within	livers,	MHC	class	II	can	be	
expressed	by	KC,	T	 cells	 and	HSC	 [28].	The	number	of	CD4	positive	 cells	 in	 liv-
ers	was	very	 low	and	did	not	correlate	with	MHC	II	expression	(data	not	shown).	
Alternatively,	 KC	may	 be	 positive	 for	MHC	 II	 after	 activation.	 Indeed,	 we	 found	
F4/80	 staining	 in	 the	 same	 region,	 although	much	more	 cells	were	positive	F4/80	
than	for	MHC	II.	F4/80	expression	did	not	change	after	treatment	with	IL-10	or	its	
PEGylated	 forms	 (Fig.	5B	and	5D),	 indicating	no	 reduction	 in	 the	number	of	KC	
cells,	but	a	reduction	in	their	activity.
IL-10	is	also	known	to	downregulate	the	expression	of	several	pro-inflammatory	
cytokines	 [29].	Analysis	 of	 IL-1β	 expression	 levels	with	PCT	methods	 (Fig	 6)	 re-
vealed	a	47%	and	51	%	reduction	 in	5PEGIL-10	and	20PEG	IL-10	 treated	groups	
respectively	(p<0.05),	whereas	unmodified	IL-10	did	not	significantly	reduce	IL-1β	

















































































Fig. 4. Antifibrotic effects of IL-10 and PEGylated IL-10 in CCl4-induced liver fibrogenesis in 
mice (A,B). Representative pictures of immunohistochemical staining for Collagen type III (A) 
and α- SMA (B) on liver cryostat sections. (C,D) Quantification of the positive stained area for 
Collagen III (C) and α- SMA (D) using the Olympus Cell D analysis program. Results are shown 
as mean ±SD (n = 6 per group). Analysis by one way ANOVA with Bonferroni post-hoc test re-
vealed that the group treated with 5PEGIL-10 displayed a reduction in collagen III (p<0.06) and 
α- SMA (*p<0.05) staining as compared to the PBS group.
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Fig. 5. Effects of IL10 and PEGylated IL10 on MHC II expression and number of Kupffer cells. 
(A, B) Representative pictures of immunohistochemical stainings for MHC class II (A) and F4/80 
(B) on mice liver sections. Animals received a single dose of CCL4 and were treated after 24 h and 
48 h with PBS, IL-10, 5PEGIL-10 or 20PEGIL-10. (C, D) Quantification of the positive stained 
area for MHC II (C) and F4/80 (D) using the Cell D image analyzing software. Results are 
shown as mean ±SD (n = 5-6 animals per group). Analysis by one way ANOVA with Bonferroni 
post-hoc test revealed that only the group treated with 5PEGIL-10 had a significant reduction 









































































Fig. 6. Effects of IL-10, 5PEGIL-10 or 20PEGIL-10 on the hepatic mRNA levels for IL-1β and IL-6. 
(A) IL-1β was significantly decreased in 5PEGIL-10 and 20PEGIL-10-treated groups as compared 
to the PBS-treated diseased mice. Unmodified IL-10 did not induce a significant decrease in IL-1β 
transcription. (*p<0.05) (B) IL-6 gene expression was significantly downregulated by IL-10 and 
both PEGylated forms of IL-10 (*p<0.05). Results are shown as mean± SD (n = 5-6 animals per 
group) and statistical analysis was performed by one way ANOVA with Bonferroni post-hoc test.
Effects of IL-10 and PEGylated forms of IL-10 on macrophages of CCL4 fibrotic livers.
Recent	studies	indicate	that	macrophages	are	cells	that	can	be	polarized	into	a	M1	




by	 Interferon-regulatory	 factor	5	 (IRF5)	 [31].	Alternatively	activated	macrophages	
(M2)	can	be	 identified	by	 the	marker	YM1	and	produce	high	amounts	of	anti-in-























Fig. 7. Western blot analysis of macrophage profiles in fibrotic livers treated with IL-10 or 
PEGylated forms of IL-10 (A). IRF5 (M1 marker) did not significantly change in any of the groups 
(B) nor did YM1 expression (M2 marker) (C). Foxp3 expression (deactivated macrophages-M2c) 
was significantly upregulated in both 5PEGIL-10 and 20PEGIL-10 -treated groups (p<0.01) (D).
Discussion
Interleukin-10	 is	 a	 potent	 anti-inflammatory	 cytokine	 that	 is	 able	 to	 decrease	 the	















biodistribution	 in	fibrotic	mice.	Studies	about	 the	pharmacokinetics	of	 IL-10	have	
been	 conducted	 in	 healthy	 individuals	 [36]	 and	 in	 renal	 disorder	 animal	models	
[37]	and	 in	 the	bile	duct	 ligated	 (BDL)	 rat	model	 for	 liver	fibrosis	 [14].	Although	
PEGylated	IL-10	has	been	previously	produced	and	tested	against	neuropathic	pain,	
it	was	used	locally	and	the	systemic	distribution	has	not	been	accessed	[18].	
Therefore,	 we	 PEGylated	 IL-10	 and	 tested	 its	 antifibrotic	 effects	 in	 vivo.	 Our	
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(see	also	Fig	2),	 and	can	also	affect	 the	phenotype	of	macrophages	by	 inducing	an	
M2c–phenotype	 [30].	These	regulatory	M2c	macrophages	have	potent	anti-inflam-
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tro and	 in vivo	 [28-30]	and	 in	2007	Rachmawati	 et	 al	 targeted	 IL-10	 to	 the	M6P/
IGFII	receptor	on	HSC	and	obtained	an	antifibrotic	effect	in	rats,	but	the	study	con-




























Computerized	 densitometry	 was	 used	 to	 measure	 the	 intensity	 of	 the	 bands	
(GeneSnap,	SYNGENE).
RAW 264.7 – Mouse embryonic cell line.	RAW	264.7	cells	(ATCC,	TIB-71)	were	cul-
tured	at	37°C	and	5%	CO2	in	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM,	Biowhittaker,	
Belgium)	 containing	 10%	 fetal	 bovine	 serum	 (FBS,	Biowhittaker,	Belgium),	 60 µg/mL	
gentamicin	(Gibco,	Invitrogen),	2mM	of	L-glutamin	(Gibco,	Invitrogen)	and	0.48	M	of	
L-arginine	(Sigma,	USA).	Cells	were	used	for	experiments	until	a	maximum	of	20	passages.
Assessment of bioactivity of constructs in vitro
RAW	 264.7	 cells	 (1.5x105	 cells/well)	 were	 cultured	 overnight	 in	 96-wells	 plates	
(Costar®,	Corning	Inc.,	USA).	First,	the	cells	were	preconditioned	for	1 h	at	37°C	in	
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t = 6 h,	TNF-α	 levels	were	determined	 in	culture	media	using	a	 sandwich	TNF-α	
ELISA	kit	(BD	PharMingen,	USA).	Experiments	were	performed	with	two	different	
batches	of	IL-10	and	PPB-PEG-IL-10	and	all	experiments	were	done	in	triplicate.


























RNeasy	kit	 (QIAGEN,	Hilden,	Germany),	 and	 the	amount	of	RNA	was	measured	
with	 the	 NanoDrop	 ND1000	 (Nanodrop	 Technologies,	 NC).	 The	 reverse	 tran-


















1310-01,	 1:250);	 MMP-13	 (Santa	 Cruz,	 SC12363,	 1:100);	 TIMP-1	 (Santa	 Cruz,	









































Fig. 1. Preparation of IL10-PEG-PPB. (A) Schematic illustration of the synthesis of IL10-PEG-
PPB. IL-10 was reacted with maleimide-PEG-succinimidyl carboxy methyl ester (MAL-PEG-
SCM, 2kDa) and subsequently with PPB-ATA (B) Western blot analysis of native and modified 
IL-10 using anti PPB (left panel) and anti-IL-10 (right panel) antibodies. It can be seen that 
IL10-PEG-PPB stains positive for PPB and IL-10 and a shift in molecular weight of IL10-PEG-





Fig. 2. Effect of IL-10 and IL10-PEG-PPB on TNFα release by RAW 264.7 cells in vitro. Cells 
were incubated with 50 ng of IL-10 and IL10-PEG-PPB 30 min before a challenge with LPS 
(25 ng/mL). It can be seen that TNF-α production by RAW 264.7 cells is significantly inhibited 
by both IL-10 and IL10-PEG-PPB (***p< 0.001 compared to LPS-stimulated cells). Results are 
expressed as mean ± SD (n = 3).
In vivo effects of IL10-PEG-PPB on collagen I.	To	study	the	effects	of	IL10-PEG-PPB	
in vivo,	we	used	the	chronic	CCl4	mouse	model.	After	8	weeks	of	CCL4	administration,	
deposition	of	fibrillar	collagen	(assessed	by	collagen	type	I	expression)	was	extensive,	



















Fig. 3. Effects of IL-10 and IL10-PEG-PPB in CCl4-induced liver fibrogenesis in mice. (A) 
Representative pictures of immunohistochemical staining for Collagen type I on liver cryostat 
sections. Animals received CCl4 injections for 8 weeks and were treated with PBS, IL-10 or IL10-
PEG-PPB (dose 10 µg\kg\day) in the last week; (B) Quantification of the positive stained area for 
Collagen I using the Olympus Cell D analysis program. Results are shown as mean ±SD (n = 6 
per group). *= p<0.05, as compared to the PBS-treated group (ANOVA).











Fig. 4. Effects of IL-10 and IL-10-PEG-PPB on the hepatic mRNA and protein levels for col-
lagen I in vivo. (A) Collagen type I mRNA levels in CCl4-injected mice treated with PBS, IL-10 
or IL10-PEG-PPB (n = 6 per group). ** = p<0.01compared to PBS and IL-10 treated mice. (B) 
Western blot analysis of collagen I deposition in CCl4-injected mice treated with PBS, IL-10 or 
IL10-PEG- PPB. * = p<0.05 compared to IL-10 or PBS-treated groups.
Effects of IL-10 and IL10-PEG-PPB on macrophages of CCL4 fibrotic livers. 
Western	blotting	 revealed	a	 significant	upregulation	of	 the	M2	marker	YM1	 (	fig.	
6A)	 and	 a	downregulation	of	 the	M1	marker	 IRF5	 (fig.	 6B)	 in	 livers	of	 the	 IL10-
PEG-PPB	 treated	 group	 as	 compared	 to	 the	 untreated	 or	 the	 IL-10	 treated	 group	












Fig. 5. Effects of IL-10 and IL10-PEG-PPB on MMP-13 and TIMP-1 expression levels in vivo. 
(A) and (B) depict protein levels as measured by Western blot analysis. (C) and (D) show mRNA 
levels as measured by rtPCR. It can be seen that IL-10 significantly affects MMP-13 levels, 
whereas IL10-PEG-PPB significantly affects TIMP-1 levels. * = p<0.05 compared to PBS-treated 
fibrotic mice.























Fig. 6. Western blot analysis of macrophage profiles in fibrotic livers treated with IL-10 or IL10-
PEG-PPB. (A) Quantitative analysis of western blots for YM1 expression (M2 marker). *= p<0.05 
compared to PBS-treated fibrotic mice. (B) Quantitative analysis of western blot for IRF5 ex-
pression (M1 marker) *= p<0.05 compared to IL-10 or PBS-treated groups. (C) Quantitative 
analysis for intrahepatic Foxp3 expression (marker for M2c- subtype). ** = p<0.01compared to 
PBS-treated group.
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Fig. 7. Effects of IL-10 on MMP-13 (A) and TIMP-1 (B) mRNA expression levels in RAW 
264.7 cells. Cells were pre-incubated with IFNγ or IL-13 24 h before incubation with IL-10 to 
induce either an M1 phenotype (IFNγ pre-incubation) or an M2 phenotype (IL-13 pre-incu-
bation). It can be seen that IL-10 exerts significant effects on MMP-13 expression only in cells 
pre-stimulated with IFNγ (M1-inducer), whereas its effects on TIMP-1 expression are most 
prominent in cells pre-stimulated with IL-13 (M2 inducer). ***= p<0.001 compared to control.
Discussion
Interleukin-10	is	a	well-known	immunoregulatory	factor	and	was	reported	to	be	a	











In	previous	 studies,	 cytokines	were	modified	 to	 improve	 the	pharmacokinetic	
or	 therapeutic	 profile	 [31,38,39].	 IL-10	was	previously	modified	with	M6P	 (M6P-
IL10)	which	induced	an	improvement	of	its	pharmacokinetic	profile	with	a	remark-
























by	KC	 [43].	The	 increased	 expression	 of	TIMP-1	 in	 livers	 induced	 by	 IL10-PEG-
PPB	 treatment	 suggests	 that	 IL10-PEG-PPB	 exerts	 its	 effects	 through	modulation	
of	HSC,	whereas	 the	 increased	 expression	of	MMP-13	observed	 after	 IL-10	 treat-
ment	indicates	that	native	IL-10	exerts	its	effects	via	KC	or	macrophages.	Activated	
HSC	have	a	high	expression	of	PDGFβ-receptor	(the	target	for	PPB)	[40],	which	is	
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In	 the	present	 study,	we	aim	 to	 further	 elucidate	 the	complex	 role	of	 IL-10	 in	
the	 interaction	between	HSCs	and	 liver	macrophages.	For	 this	purpose	 IL-10	was	
chemically	modified	with	PPB,	the	cyclic	peptide	that	binds	to	the	PDGF-β-receptor,	







IL10-PEG-PPB synthesis, characterization and activity. The	conjugation	and	charac-
terization	of	PPB	to	IL-10	was	done	according	to	a	similar	procedure	as	for	Interferon	
γ	 [30].	Briefly,	50 µg/mL	of	human	IL-10	(rhIL-10,	PeproTech	EC	Ltda.,	UK)	was	
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Biotechnology,	 USA)	 IgGs.	 Suitable	 secondary	 and	 third	 antibodies	 were	 applied	
and	visualized	with	3-amino-9-ethylcarbazole	(AEC,	Sigma),	according	to	standard	
methods.	Staining	of	MHC	class	 II	was	quantified	by	 image	analyzing	 techniques,	
using	Multiple	Alignment	Analysis	(MIAs).	The	results	were	given	as	percentages	of	
positive-stained	areas	divided	by	the	total	area	of	the	section.	
Real-Time PCR.	 Isolation	of	 total	RNA	from	mice	 livers	was	performed	using	 the	
RNeasy	kit	 (QIAGEN,	Hilden,	Germany),	 and	 the	amount	of	RNA	was	measured	
with	 the	 NanoDrop	 ND1000	 (Nanodrop	 Technologies,	 NC).	 The	 reverse	 tran-
scriptase	 reaction	 was	 done	 using	 random	 primers	 (Promega).	The	 transcription	
levels	of	mice	collagen	III	(forward	5’ACGTGGTAGTCCTGGTGGTC3’	and	reverse	
5’GCTGGTCCAGCATCACCTTTT3’),	 α-SMA	 (forward	 5’ACTACTGCCGAG-	
CGTCAGAT3’	and	reverse	5’CCAAATGAAAGATGGCTGGAA3’),	F4/80	(forward	
5’TGCAATCTAGCAATGGACAGC3’	 and	 reverse	 5’GCCTTCTGGATCCAT-
TTGAA3’),	 CCR2	 (forward	 5’AGGGCATTGGATTCACCACAT3’	 and	 reverse	
5’TACGGTGTGGTGGCCCCTTCA3’),	 and	 IL-10	 (forward	 5’ATAACTGCACCC-













































Fig. 1. Effects of IL-10 and IL10-PEG-PPB in CCl4-induced liver fibrogenesis in mice (n = 6 
per group). Animals received CCL4 injections for 8 weeks and were treated with PBS, IL-10 or 
IL10-PEG-PPB (dose 10 µg\kg\day) in the last week. (A) Representative pictures of immunohis-
tochemical staining for Collagen type III on liver cryostat sections. (B) mRNA levels for collagen 
type III in the different experimental groups (***p<0.001 compared to PBS and IL-10 treated 
animals). (C) Western blot analysis of fibronectin protein expression levels; *** = p<0.001 in the 
IL10-PEG-PPB treated group as compared to the untreated and IL-10 treated groups.
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Collagen	 III	mRNA	expression	 (***p<0.001)	compared	 to	untreated	fibrotic	mice.	
Also	fibronectin	levels,	representing	another	constituent	of	the	extracellular	matrix,	
were	 significantly	 increased	 in	 IL10-PEG-PPB-treated	 fibrotic	mice,	 compared	 to	
mice	receiving	vehicle	after	CCl4	administrations	(Fig	1C).	(***p<0.001).	
A B
Fig. 2. Effects of IL-10 and IL-10-PEG-PPB on activated hepatic stellate cells (HSC). (A) 
α-SMA mRNA expression levels and (B) western blot analysis of α-SMA in fibrotic mice receiv-
ing vehicle (PBS), native Il-10 or modified IL-10 (IL10-PEG-PPB). No significant differences 
were observed between groups.











receiving	 native	 IL-10	 (*p<0.05).	The	 lack	 of	 effect	 of	 the	HSC-specific	 construct	





upregulated	 in	both	groups	 (Fig.	4B;	 **p<0.01	 for	 IL-10	and	***p<0.001	 for	 IL10-
PEG-PPB)	as	compared	to	the	control.
*
Fig. 3. Effects of IL-10 and IL10-PEG-PPB on number of macrophages. Real time PCR showing 
significant increase in gene expression for F4/80 in the IL10-PEG-PPB-treated group as com-
pared to animals treated with IL-10 or the untreated group. (*= p<0.05).



















Fig. 4. Effects of IL-10 and IL10-PEG-PPB on CCR2 and CCL2 levels. (A) Expression levels of 
mRNA for CCR2 in fibrotic mice receiving different treatments. *= p<0.05 and **= p<0.01 as 
compared to vehicle-(PBS)-treated group; (B) Western blot analysis of CCL2 protein levels in the 














Fig. 5. Effects of IL-10 and IL10-PEG-PPB on MHC II, IL-10 and TGFβ on fibrotic livers. (A) 
Representative pictures of immunohistochemical staining for MHC class II on liver cryostat sec-
tions; (B) Quantification of the positive stained area for MHC class II using the Olympus Cell D 
analysis program. *= p<0.05 as compared to untreated and IL-10 treated groups; (C) mRNA ex-
pression levels of IL-10. *= p<0.05 as compared to the PBS and to IL0-PEG-PPB-treated groups; 
(D) Gene expression levels for TGFβ in different experimental groups. *= p<0.05 as compared to 
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Fig. 6. Schematic overview of the proposed HSC-macrophage interaction and an overview of the 
markers for the different subtypes of macrophages used in the present study. The combination 















and	 lungs	 [25-27,43].	Recently	we	 found	 that	PEGylation	of	 IL-10,	causing	a	pro-
longed	bioavailability	of	 IL-10	 in vivo,	attenuated	hepatic	fibrosis	and	 intrahepatic	
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HSC	in	fibrotic	 livers	 [46-48].	We	used	this	peptide	here	 to	deliver	 IL-10	 to	HSC.	




jugate	 showing	 increased	 accumulation	of	ECM	components	 after	 IL10-PEG-PPB	
administration.	Surprisingly,	neither	the	conjugate	nor	the	native	IL-10	had	an	ef-
fect	on	α-SMA	expression,	the	marker	for	activated	HCS	(fig.	2A	and	2B),	although	
IL-10	was	directed	 to	 this	 cell	 type.	We	neither	did	 see	 an	 increased	 apoptosis	 of	
HSC,	as	reported	in	other	studies	[49]	but	this	may	be	caused	by	the	short-term	IL-
10	treatment	in	the	present	experiments.	However,	significant	effects	were	found	on	
the	macrophage	population.	Targeting	of	 IL-10	 to	 the	HSCs	 induced	a	 significant	
increase	in	the	number	of	Kupffer	cells	(fig.	3)	as	reflected	by	the	upregulation	of	its	
marker	F4/80	[50].	In vitro	studies	recently	have	shown	that	activated	rat	HSCs	are	




tant	 role	 in	 the	 pathogenesis	 of	 liver	 fibrosis.	 Classically	 activated	macrophages	




tivated	by	 immune	complexes	 combined	with	 IL1-R	or	TLR	agonists),	 and	M2c	
(activated	 by	 IL-10,	 TGFβ	 or	 glucocorticoids)	 [52-55].	 Recent	 studies	 showed	
that	HSC	are	able	to	affect	macrophages	by	production	of	the	chemotactic	factor	
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therefore	applied	a	 cell-specific	delivery	approach	 for	 IL-10,	 thus	mimicking	 local	
production	of	this	cytokine.	
In	the	present	thesis,	we	describe	the	successful	preparation	of	a	conjugate	that	
is	selectively	delivered	to	HSC	 in vivo	during	 liver	fibrogenesis	 in	mice.	IL-10	was	
chemically	modified	with	 a	 cycle	peptide	 (PPB)	 that	 binds	 to	 the	 (overexpressed)	
PDGFβ	receptor	on	activated	HSC.	A	PEG	linker	of	2	kDa	between	IL-10	and	this	
peptide	was	used	to	provide	stability	and	flexibility	to	the	molecule.	Our	studies	on	
the	effects	of	 this	conjugate	 in vivo	 yield	new	 insights	 into	 the	direct	and	 indirect	
effects	of	IL-10	on	HSC	and	provide	evidence	for	cross-talk	between	these	cells	and	
liver	macrophages.	The	targeting	of	IL-10	or	other	biological	mediators	to	different	


























































Summary, general discussion and future perspectives
6






























































modify	macrophage	 influx	 and	macrophage	 polarization	 in	 fibrotic	 livers	 thereby	
modifying	this	pathological	process.	
Conclusions and future perspectives
In	summary,	the	aim	of	the	studies	described	in	this	thesis	focuses	on	the	role	of	




Upon	 PEGylation,	 the	 circulation	 time	was	 prolonged,	which	was	 associated	
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circulation	time	after	PEGylation.	Since	macrophages	are	known	to	express	more	





















polarization	 into	the	M2-subtype,	whereas	 it	also	affects	 the	macrophage	popula-
tion	 thereby	creating	an	anti-fibrogenic	 response	possibly	via	modification	of	 the	
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Dit	 proefschrift	 beschrijft	 de	 effecten	 van	 een	 cel-specifieke	 aflevering	 van	
Interleukine-10	 in	 de	Hepatische	 Stellaat	 cel.	Cytokines	 zoals	 Interleukine-10	 zijn	









































De	 bestaande	 literatuur	 liet	 zien	 dat	 het	 effect	 van	 interleukine-10	 tijdens	 het	






daarmee	de	kans	verhoogd	wordt	dat	 Interleukine-10	het	 zieke	weefsel	bereikt	 en	
(2)	door	het	cytokine	gericht	te	sturen	naar	de	cellen	die	het	belangrijkste	zijn	bij	het	
ontstaan	van	leverfibrose:	de	hepatische	stellaat	cellen.
De	overlevingstijd	van	cytokines	 in	het	bloed	 is	meestal	 vrij	 kort	 (zo	ook	van	
Interleukine-10)	waardoor	het	 cytokine	het	doel	orgaan	 in	onvoldoende	mate	be-
reikt.	 Cytokines	 worden	 normaliter	 lokaal	 geproduceerd	 en	 hun	 belangrijkste	 ef-
fecten	 zijn	 ook	 vaak	 lokaal.	 Opruimmechanismen	 in	 het	 lichaam	 zorgen	 ervoor	
dat	cytokines	ook	vaak	alleen	lokaal	actief	zijn	en	juist	dit	blokkeert	het	systemisch	
therapeutisch	 gebruik	 van	 de	meeste	 cytokines.	 Pegylering	 van	 diverse	 cytokines	
(met	name	Interferonen)	bleek	al	zeer	succesvol:	door	de	verlengde	overlevingstijd	
kwam	er	bijvoorbeeld	meer	Interferon	α2	(a	en	b)	in	de	lever	terecht	en	werden	de	
antivirale	 effecten	 van	deze	 cytokines	 in	 de	 lever	 versterkt.	Op	het	 gebied	 van	de	
bestrijding	 van	 Hepatitis	 heeft	 dit	 tot	 een	 doorbraak	 geleid.	Wij	 hebben	 daarom	
eerst	bij	 Interleukine-10	dezelfde	 strategie	 toegepast.	Deze	 studies	zijn	beschreven	
in	Hoofdstuk 3.	 Pegylering	 van	 Interleukine	 10	 verlengde	 sterk	de	halfwaardetijd	
in	bloedplasma	en	 leidde	tot	een	significant	verhoogde	accumulatie	 in	de	 lever	en	
een	 significante	 verbetering	 van	 de	 anti-fibrotische	 activiteit	 in	 de	 fibrotische	 le-
ver	bij	muizen	 ten	opzichte	van	onveranderd	 Interleukine-10.	We	hebben	 in	onze	
studies	twee	verschillende	molecuul	groottes	getest	(PEG	5	Kd	en	PEG	20	Kd).	Uit	
onze	 resultaten	 bleek	 dat	 het	 kleinste	 PEG	molecuul	 al	 grote	 effecten	 had	 op	 de	
overlevingstijd	 in	plasma	en	niet	de	binding	van	Interleukine-10	aan	zijn	receptor	
verstoorde.	 De	 anti-fibrotische	 effecten	 van	 PEG5kd-Interleukine-10	 bleken	 in	 het	
proefdiermodel	 significant	beter	 ten	opzichte	van	onveranderd	 Interleukine-10	 en	
PEG20kd-Interleukine-10.	We	concludeerden	dat	PEGylering	van	Interleukine-10	een	
zinvolle	strategie	is	en	leidt	tot	anti-fibrotische	effecten	in	ons	muis	model.
























Prostaglandine	 J2.	Uit	 de	 literatuur	 bleek	 dat	 dit	 prostaglandine	 apoptosis	 (gepro-
grammeerde	celdood)	kan	 induceren	 in	hepatische	stellaat	cellen	en	daarmee	ook	
een	 anti-fibrotisch	 effect	 kan	uitoefenen.	Prostaglandines	hebben	 in	het	 algemeen	
ook	een	zeer	korte	halfwaarde	tijd	in	bloed,	reden	voor	ons	om	te	testen	of	deze	stof	
ook	specifiek	is	af	te	leveren	in	deze	doelcellen.	Deze	studies	toonden	aan	dat	beide	


































hoofdstuk 5)	gericht	op	de	 interactie	 tussen	hepatische	stellaat	cellen	en	macrofa-
gen.	Uit	deze	 studies	bleek	dat	 in	de	 levers	van	muizen	die	behandeld	waren	met	
PPB-PEG-Interleukine-10	een	verhoogde	aanwezigheid	was	van	stoffen	die	macro-








(positief	 voor	CCR2)	worden	 aangetrokken.	Deze	macrofagen	 stimuleren	 op	 hun	




Wij	 concluderen	 in	 hoofdstuk 6	 dat	 door	 onze	 studies	 veel	 duidelijk	 is	 ge-
worden	over	de	 rol	 van	 Interleukine	10	 tijdens	 leverfibrose.	 Interleukine-10	beïn-
vloedt	het	fibrose	proces	op	verschillende	manieren:	 intraveneuze	 toediening	 leidt	























Esta	 tese	 descreve	 os	 efeitos	 de	 um	 endereçamento	 específico	 de	 Interleucina-10	
























hepática	 conhecida	por	 cirrose.	Não	existe	 terapia	 eficaz	disponível	para	a	 cirrose	
hepática	e	a	única	forma	de	tratamento	é	o	transplante	de	fígado.	Assim	sendo,	novos	
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sweet	and	mamãe	loves	you	so	much!	You	are	a	very	smart	and	big	6-year-old	boy	
and	I	am	also	very	proud	of	you.	I	would	like	to	apologize	for	not	having	a	lot	of	free	
time	to	enjoy	being	with	you	more.	I	hope	you	understand	that	and	I	wish	I	have	
more	time	from	now	on	to	catch	up	
Adriana

